Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Go back to Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 199.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $199.71 | 52 Week Low | $223.02 | |||
| Day High | $199.71 | P/E | 25.57 | |||
| Day Low | $199.71 | EPS | $7.81 | |||
| Volume | 2,062 | |||||
